<DOC>
	<DOCNO>NCT00189761</DOCNO>
	<brief_summary>A study ass efficacy , safety pharmacokinetics tacrolimus new oral formulation ( MR4 ) de novo bone marrow transplant recipient</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety Pharmacokinetics Tacrolimus New Oral Formulation ( MR4 ) BMT Recipients</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Bone marrow transplantation patient age 2054 except transplant genetically HLA match sibling donor . The patient fully inform . The patient severe impaired hepatic function . The patient impair renal function . The patient exist complication severe cardiac dysfunction . The patient severe impaired pulmonary function .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Graft versus Host Disease</keyword>
</DOC>